Latest Pharma and Biotech News
Biotechnology
13 October 2026 Swiss pharma giant Roche has entered into another obesity focused collaboration, this time for rights for Rona Therapeutics' investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary extrahepatic delivery platform.
Today's issue
Refine search
Pharmaceutical
Lonza Group shares climbed 2.5% following the company’s announcement of upgraded mid-term financial targets and confirmation of its 2026 outlook. 14 October 2026
Biotechnology
US generative biology company Generate Biomedicines has signed a multi-target collaboration and license agreement with Zealand Pharma, the Danish metabolic disease biotech, to design multispecific protein therapeutics for obesity and other metabolic diseases using Generate’s AI platform. 14 October 2026
Pharmaceutical
US immune-mediated diseases specialist Alumis has announced new envudeucitinib data from the ONWARD Phase III clinical program - ONWARD1, ONWARD2, and the long-term extension ONWARD3. 14 October 2026
Biotechnology
Intellia Therapeutics, a US biopharma utilizing CRISPR gene editing technology, announced the appointment of Dr Jing Marantz as executive vice president and chief medical officer (CMMO). This appointment is effective October 26, 2026. 14 October 2026
Biotechnology
Alaunos Therapeutics announced the completion of the acquisition of Velaris Therapeutics, a privately-held biotechnology company advancing a pipeline of potentially transformative therapies for pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases. 14 October 2026
Pharmaceutical
Delivering radiation to a tumor through an injected medicine involves a supply chain that begins well before a patient reaches hospital. Nuclear facilities produce the radioactive material, specialist manufacturers turn it into a drug, and delivery teams work to a timetable set partly by radioactive decay. 14 October 2026
Biotechnology
German biotech BioNTech has reported a setback for its experimental mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran), after a late-stage study failed to show a statistically significant improvement in progression-free survival (PFS). 14 October 2026
Biotechnology
US biotech company Syndax Pharmaceuticals has dropped plans to develop axatilimab for idiopathic pulmonary fibrosis (IPF) after a Phase II trial missed its primary endpoint, closing off a potential new indication for the antibody. 14 October 2026
Biotechnology
French biotech company Transgene has appointed Anne Stehlin as chief quality officer and responsible pharmacist, giving her oversight of quality across research, clinical development, manufacturing and pharmaceutical operations. 14 October 2026
Biotechnology
The Alzheimer’s disease (AD) market across the eight major markets (8MM USA, France, Germany, Italy, Spain, UK, Japan, and China ) is forecast to increase from $2.4 billion in 2023 to $14.7 billion by 2033, at a compound annual growth rate (CAGR) of 20.0%. 14 October 2026
Pharmaceutical
US bio pharma Liquidia Corp has entered into a global settlement agreement with United Therapeutics that resolves all pending litigation between the companies. Importantly, Yutrepia (treprostinil) inhalation powder will remain available to patients with pulmonary arterial hypertension (PAH) without disruption. 14 October 2026
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) today authorised Onswik (insulin efsitora alfa) for the treatment of type 2 diabetes mellitus in adults. The marketing authorization was granted Eli Lilly. 13 October 2026
Pharmaceutical
Boston, USA-based computational drug discovery company Nimbus Therapeutics has made three senior appointments as it expands its business development and research capabilities. 13 October 2026
Biotechnology
Swiss pharma giant Roche has entered into another obesity focused collaboration, this time for rights for Rona Therapeutics' investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary extrahepatic delivery platform. 13 October 2026
Pharmaceutical
US healthcare major Johnson & Johnson reported third-quarter 2026 sales of $25.4 billion, up 5.9% year-on-year from $23.99 billion and ahead of analyst consensus of around $25.28 billion. 13 October 2026
Biotechnology
US clinical-stage biotech Tortugas Neuroscience has announced positive Phase IIb trial results for obuprazine (TRTL-107), the company's investigational treatment for schizophrenia. 13 October 2026
Biotechnology
Italy's Sibylla Biotech, an oncology firm developing small-molecule protein degraders that interfere with protein folding, has appointed Usman Azam as chief executive and Gianluca Fuggetta as chief financial officer, as it prepares to take its lead program into first-in-human studies. 13 October 2026
Biosimilars
Germany’s Formycon and India’s Zydus Lifesciences jointly announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda (pembrolizumab). 13 October 2026
Pharmaceutical
Telix Pharmaceuticals began US commercial supply of Pixclara (floretyrosine F 18), while Knight Therapeutics launched Tavalisse (fostamatinib) in Brazil. Separately, community reimbursement for Novo’s Alhemo (concizumab) took effect in France for bleeding prevention in patients aged 12 or older with hemophilia B and factor IX inhibitors, an access change for an already-marketed medicine. 13 October 2026
Pharmaceutical
Bristol Myers Squibb said its Phase III ALOFT-IPF trial of admilparant, an oral LPA1 receptor antagonist, met its primary endpoint at the 60mg dose in adults with idiopathic pulmonary fibrosis (IPF), showing a statistically significant improvement over placebo in absolute change in forced vital capacity (FVC) at week 52. 13 October 2026
All news
Pharmaceutical
Lonza Group shares climbed 2.5% following the company’s announcement of upgraded mid-term financial targets and confirmation of its 2026 outlook. 14 October 2026
Biotechnology
US generative biology company Generate Biomedicines has signed a multi-target collaboration and license agreement with Zealand Pharma, the Danish metabolic disease biotech, to design multispecific protein therapeutics for obesity and other metabolic diseases using Generate’s AI platform. 14 October 2026
Pharmaceutical
US immune-mediated diseases specialist Alumis has announced new envudeucitinib data from the ONWARD Phase III clinical program - ONWARD1, ONWARD2, and the long-term extension ONWARD3. 14 October 2026
Biotechnology
Intellia Therapeutics, a US biopharma utilizing CRISPR gene editing technology, announced the appointment of Dr Jing Marantz as executive vice president and chief medical officer (CMMO). This appointment is effective October 26, 2026. 14 October 2026
Biotechnology
Alaunos Therapeutics announced the completion of the acquisition of Velaris Therapeutics, a privately-held biotechnology company advancing a pipeline of potentially transformative therapies for pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases. 14 October 2026
Pharmaceutical
Delivering radiation to a tumor through an injected medicine involves a supply chain that begins well before a patient reaches hospital. Nuclear facilities produce the radioactive material, specialist manufacturers turn it into a drug, and delivery teams work to a timetable set partly by radioactive decay. 14 October 2026
Biotechnology
German biotech BioNTech has reported a setback for its experimental mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran), after a late-stage study failed to show a statistically significant improvement in progression-free survival (PFS). 14 October 2026
Biotechnology
US biotech company Syndax Pharmaceuticals has dropped plans to develop axatilimab for idiopathic pulmonary fibrosis (IPF) after a Phase II trial missed its primary endpoint, closing off a potential new indication for the antibody. 14 October 2026
Biotechnology
French biotech company Transgene has appointed Anne Stehlin as chief quality officer and responsible pharmacist, giving her oversight of quality across research, clinical development, manufacturing and pharmaceutical operations. 14 October 2026
Biotechnology
The Alzheimer’s disease (AD) market across the eight major markets (8MM USA, France, Germany, Italy, Spain, UK, Japan, and China ) is forecast to increase from $2.4 billion in 2023 to $14.7 billion by 2033, at a compound annual growth rate (CAGR) of 20.0%. 14 October 2026
Pharmaceutical
US bio pharma Liquidia Corp has entered into a global settlement agreement with United Therapeutics that resolves all pending litigation between the companies. Importantly, Yutrepia (treprostinil) inhalation powder will remain available to patients with pulmonary arterial hypertension (PAH) without disruption. 14 October 2026
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) today authorised Onswik (insulin efsitora alfa) for the treatment of type 2 diabetes mellitus in adults. The marketing authorization was granted Eli Lilly. 13 October 2026
Pharmaceutical
Boston, USA-based computational drug discovery company Nimbus Therapeutics has made three senior appointments as it expands its business development and research capabilities. 13 October 2026
Biotechnology
Swiss pharma giant Roche has entered into another obesity focused collaboration, this time for rights for Rona Therapeutics' investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary extrahepatic delivery platform. 13 October 2026
Pharmaceutical
US healthcare major Johnson & Johnson reported third-quarter 2026 sales of $25.4 billion, up 5.9% year-on-year from $23.99 billion and ahead of analyst consensus of around $25.28 billion. 13 October 2026
Biotechnology
US clinical-stage biotech Tortugas Neuroscience has announced positive Phase IIb trial results for obuprazine (TRTL-107), the company's investigational treatment for schizophrenia. 13 October 2026
Biotechnology
Italy's Sibylla Biotech, an oncology firm developing small-molecule protein degraders that interfere with protein folding, has appointed Usman Azam as chief executive and Gianluca Fuggetta as chief financial officer, as it prepares to take its lead program into first-in-human studies. 13 October 2026
Biosimilars
Germany’s Formycon and India’s Zydus Lifesciences jointly announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda (pembrolizumab). 13 October 2026
Pharmaceutical
Telix Pharmaceuticals began US commercial supply of Pixclara (floretyrosine F 18), while Knight Therapeutics launched Tavalisse (fostamatinib) in Brazil. Separately, community reimbursement for Novo’s Alhemo (concizumab) took effect in France for bleeding prevention in patients aged 12 or older with hemophilia B and factor IX inhibitors, an access change for an already-marketed medicine. 13 October 2026
Pharmaceutical
Bristol Myers Squibb said its Phase III ALOFT-IPF trial of admilparant, an oral LPA1 receptor antagonist, met its primary endpoint at the 60mg dose in adults with idiopathic pulmonary fibrosis (IPF), showing a statistically significant improvement over placebo in absolute change in forced vital capacity (FVC) at week 52. 13 October 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze